 Robert Jotte
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 32 | 2026 | 2642 | 2.150 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 25 | 2026 | 1182 | 2.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 24 | 2025 | 1958 | 1.530 |
Why?
| | Bevacizumab | 10 | 2025 | 167 | 0.730 |
Why?
| | Antibodies, Monoclonal, Humanized | 13 | 2025 | 988 | 0.650 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2020 | 642 | 0.610 |
Why?
| | Small Cell Lung Carcinoma | 4 | 2021 | 119 | 0.600 |
Why?
| | Carboplatin | 12 | 2025 | 160 | 0.590 |
Why?
| | Anthracyclines | 3 | 2014 | 47 | 0.520 |
Why?
| | Pyrimidines | 4 | 2025 | 533 | 0.510 |
Why?
| | Antineoplastic Agents | 7 | 2025 | 2197 | 0.490 |
Why?
| | Paclitaxel | 10 | 2025 | 256 | 0.490 |
Why?
| | Topotecan | 2 | 2014 | 17 | 0.440 |
Why?
| | Topoisomerase I Inhibitors | 2 | 2012 | 19 | 0.430 |
Why?
| | Quinazolines | 3 | 2025 | 266 | 0.370 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 434 | 0.370 |
Why?
| | Precision Medicine | 1 | 2015 | 458 | 0.330 |
Why?
| | Neoplasms | 4 | 2025 | 2884 | 0.300 |
Why?
| | Immunotherapy | 2 | 2025 | 657 | 0.260 |
Why?
| | Middle Aged | 28 | 2026 | 35928 | 0.240 |
Why?
| | Cisplatin | 4 | 2020 | 334 | 0.230 |
Why?
| | Aged | 23 | 2026 | 25947 | 0.230 |
Why?
| | Acrylamides | 1 | 2025 | 70 | 0.220 |
Why?
| | Aniline Compounds | 1 | 2025 | 119 | 0.220 |
Why?
| | Aged, 80 and over | 13 | 2025 | 8279 | 0.210 |
Why?
| | Albumins | 3 | 2020 | 118 | 0.210 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 253 | 0.210 |
Why?
| | Glutamates | 3 | 2013 | 66 | 0.210 |
Why?
| | Guanine | 3 | 2013 | 87 | 0.200 |
Why?
| | ErbB Receptors | 4 | 2025 | 629 | 0.200 |
Why?
| | Genetic Therapy | 1 | 2025 | 313 | 0.200 |
Why?
| | Maximum Tolerated Dose | 3 | 2025 | 212 | 0.200 |
Why?
| | Antibodies, Monoclonal | 4 | 2018 | 1524 | 0.200 |
Why?
| | Benzamides | 2 | 2014 | 224 | 0.180 |
Why?
| | Adult | 22 | 2025 | 40506 | 0.180 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 1 | 2022 | 12 | 0.180 |
Why?
| | Mutation | 7 | 2025 | 4099 | 0.180 |
Why?
| | Humans | 40 | 2026 | 144957 | 0.170 |
Why?
| | Erlotinib Hydrochloride | 3 | 2020 | 72 | 0.170 |
Why?
| | B7-H1 Antigen | 2 | 2025 | 241 | 0.170 |
Why?
| | Male | 27 | 2026 | 72406 | 0.160 |
Why?
| | Female | 28 | 2026 | 78376 | 0.160 |
Why?
| | Treatment Outcome | 12 | 2025 | 11695 | 0.160 |
Why?
| | Biomarkers, Tumor | 2 | 2026 | 1322 | 0.160 |
Why?
| | Taxoids | 3 | 2017 | 116 | 0.160 |
Why?
| | Survival Analysis | 5 | 2021 | 1385 | 0.150 |
Why?
| | Deoxycytidine | 3 | 2020 | 221 | 0.150 |
Why?
| | Pyrroles | 1 | 2021 | 218 | 0.150 |
Why?
| | Lymphoma | 1 | 2020 | 233 | 0.140 |
Why?
| | Melanoma | 1 | 2025 | 761 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 531 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2025 | 847 | 0.130 |
Why?
| | Neoplasm Metastasis | 3 | 2026 | 695 | 0.120 |
Why?
| | Neoplasm Staging | 6 | 2021 | 1465 | 0.120 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2015 | 117 | 0.110 |
Why?
| | Multigene Family | 1 | 2015 | 204 | 0.110 |
Why?
| | Indoles | 2 | 2025 | 501 | 0.110 |
Why?
| | Dacarbazine | 1 | 2014 | 100 | 0.110 |
Why?
| | Pyridines | 2 | 2023 | 605 | 0.100 |
Why?
| | Carcinoma, Large Cell | 2 | 2010 | 17 | 0.100 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 109 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2017 | 883 | 0.100 |
Why?
| | Disease-Free Survival | 4 | 2019 | 769 | 0.090 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2012 | 23 | 0.090 |
Why?
| | Polyethylene Glycols | 2 | 2020 | 655 | 0.090 |
Why?
| | Drug Administration Schedule | 4 | 2020 | 783 | 0.090 |
Why?
| | Quality of Life | 4 | 2019 | 3192 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 4 | 2017 | 966 | 0.090 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 257 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2013 | 675 | 0.080 |
Why?
| | Intention to Treat Analysis | 1 | 2010 | 80 | 0.080 |
Why?
| | Medical Oncology | 1 | 2014 | 332 | 0.080 |
Why?
| | Young Adult | 6 | 2021 | 14126 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 581 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 220 | 0.080 |
Why?
| | Neutropenia | 1 | 2010 | 155 | 0.080 |
Why?
| | Nanoparticles | 2 | 2020 | 520 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 970 | 0.070 |
Why?
| | Thrombocytopenia | 1 | 2010 | 205 | 0.070 |
Why?
| | Pemetrexed | 3 | 2013 | 38 | 0.070 |
Why?
| | Etoposide | 2 | 2010 | 167 | 0.060 |
Why?
| | Acetonitriles | 1 | 2025 | 13 | 0.060 |
Why?
| | Prognosis | 3 | 2022 | 4293 | 0.060 |
Why?
| | Survival Rate | 3 | 2020 | 2092 | 0.060 |
Why?
| | Apoptosis | 2 | 2003 | 2430 | 0.050 |
Why?
| | Liver Neoplasms | 2 | 2021 | 783 | 0.050 |
Why?
| | Reoviridae | 1 | 2003 | 38 | 0.050 |
Why?
| | Signal Transduction | 2 | 2015 | 5233 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2025 | 264 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2010 | 931 | 0.050 |
Why?
| | Piperazines | 1 | 2025 | 381 | 0.050 |
Why?
| | Anilides | 1 | 2023 | 84 | 0.050 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 2002 | 38 | 0.040 |
Why?
| | I-kappa B Proteins | 1 | 2002 | 74 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2852 | 0.040 |
Why?
| | DNA Repair | 1 | 2003 | 256 | 0.040 |
Why?
| | Spermine | 1 | 2020 | 29 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2020 | 42 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 1325 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2032 | 0.040 |
Why?
| | Fluorouracil | 1 | 2020 | 235 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 496 | 0.040 |
Why?
| | Cell Cycle | 1 | 2002 | 597 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2020 | 310 | 0.040 |
Why?
| | Genes, erbB-1 | 1 | 2018 | 21 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 735 | 0.030 |
Why?
| | NF-kappa B | 1 | 2002 | 662 | 0.030 |
Why?
| | Retreatment | 1 | 2017 | 77 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 2018 | 118 | 0.030 |
Why?
| | Adolescent | 2 | 2021 | 22453 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 1217 | 0.030 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 1268 | 0.030 |
Why?
| | United States | 2 | 2013 | 15988 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5417 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1721 | 0.030 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 230 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1054 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 199 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2002 | 1462 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 557 | 0.030 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2014 | 34 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1141 | 0.030 |
Why?
| | Prospective Studies | 1 | 2026 | 7997 | 0.020 |
Why?
| | Medical Records | 1 | 2014 | 189 | 0.020 |
Why?
| | Liver | 1 | 2021 | 1888 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2002 | 2609 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2021 | 1322 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1077 | 0.020 |
Why?
| | Quality Assurance, Health Care | 1 | 2014 | 340 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2003 | 758 | 0.020 |
Why?
| | Cadherins | 1 | 2012 | 201 | 0.020 |
Why?
| | Albumin-Bound Paclitaxel | 1 | 2009 | 1 | 0.020 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2009 | 20 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 732 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2010 | 289 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1835 | 0.020 |
Why?
| | Brain | 1 | 2021 | 2941 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2014 | 693 | 0.020 |
Why?
| | Tetrahydronaphthalenes | 1 | 2008 | 31 | 0.020 |
Why?
| | Hypertriglyceridemia | 1 | 2008 | 44 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2008 | 252 | 0.020 |
Why?
| | Cell Line | 2 | 2003 | 2882 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2147 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2010 | 1095 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1358 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2022 | 17101 | 0.010 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2003 | 94 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 7183 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 512 | 0.010 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2002 | 49 | 0.010 |
Why?
| | DNA Fingerprinting | 1 | 2002 | 32 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 54 | 0.010 |
Why?
| | Endoplasmic Reticulum | 1 | 2003 | 266 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2002 | 187 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2002 | 541 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 919 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1718 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1371 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1629 | 0.010 |
Why?
| | Proteins | 1 | 2002 | 1022 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2002 | 1786 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1500 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2456 | 0.000 |
Why?
| | Mice | 1 | 2003 | 18365 | 0.000 |
Why?
| | Animals | 1 | 2003 | 38109 | 0.000 |
Why?
|
|
Jotte's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|